Another treatment option for advanced breast cancer. The FDA has approved imlunestrant plus abemaciclib for certain patients with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic disease.
@thecancersurvivorsclub.com
@thecancersurvivorsclub.comAnother treatment option for advanced breast cancer. The FDA has approved imlunestrant plus abemaciclib for certain patients with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic disease.
@thecancersurvivorsclub.comSometimes hope means travelling 1,700 miles to find the care you need. After a gynecologic cancer diagnosis and limited access to specialist treatment, Nan Magdits travelled across the US in search of another chance.
@thecancersurvivorsclub.comEncouraging results in HER2-mutant lung cancer. Enhertu achieved median progression-free survival of 14.3 months versus 8.3 months with chemotherapy plus immunotherapy in DESTINY-Lung04.
@thecancersurvivorsclub.comProstate cancer treatment is becoming increasingly personalized. Genetic testing, targeted treatments, radioligand therapy and emerging immunotherapies are helping doctors match treatment more closely to individual cancers.
@thecancersurvivorsclub.comA new approach to pancreatic cancer treatment delivers chemotherapy directly into the tumor. TAMP uses a catheter to target the cancer while potentially reducing the whole-body effects of chemotherapy.
@thecancersurvivorsclub.comScientists may have found a new way to help the immune system see hard-to-treat cancers. Dana-Farber research suggests changing the targets displayed by cancer cells could help turn some “cold” tumors “hot.”
@thecancersurvivorsclub.comTreatment options for non-Hodgkin lymphoma continue to expand. Bispecific antibodies, CAR T-cell therapy and targeted treatments are reshaping care and giving doctors more ways to treat different forms of lymphoma.
@thecancersurvivorsclub.comMore encouraging news for pancreatic cancer. The FDA has granted Breakthrough Therapy designation to daraxonrasib plus chemotherapy as a potential first-line treatment for metastatic pancreatic cancer.
@thecancersurvivorsclub.comCancer treatment using sound waves is moving forward. The University of Michigan has launched a new Histotripsy Center to expand research into a non-invasive technology that mechanically destroys tumors.
@thecancersurvivorsclub.comEncouraging progress in lung cancer. New antibody-drug conjugates showed significant survival benefits in small cell lung cancer, while Enhertu delivered promising results in HER2-positive disease.
@thecancersurvivorsclub.comPrecision medicine continues to change lung cancer care. For some patients with EGFR-mutated lung cancer, targeted treatment after surgery can reduce recurrence risk and improve survival.
@thecancersurvivorsclub.comCould a blood test help personalise chemotherapy after colon cancer surgery? A Phase 2 study suggests circulating tumour DNA could help identify who may need more or less treatment.
@thecancersurvivorsclub.comMore encouraging lung cancer research. Tagrisso plus Orpathys significantly improved progression-free survival in a Phase 3 trial for patients with advanced EGFR-mutated lung cancer and MET overexpression.
@thecancersurvivorsclub.comLong-term survival continues to improve for some people with EGFR-mutated lung cancer. Tagrisso has produced encouraging long-term survival results following surgery for early-stage disease.
@thecancersurvivorsclub.comEncouraging early CAR T results: a patient with relapsed AL amyloidosis achieved complete remission within weeks of treatment and has needed no further cancer therapy for more than a year.
@thecancersurvivorsclub.comProstate cancer treatment has changed dramatically in five years. New targeted drugs, PSMA therapies and improved imaging are giving doctors more ways to personalise treatment and patients more options.
@thecancersurvivorsclub.comA new option for some advanced abdominal cancers. PIPAC delivers chemotherapy directly into the abdomen as a pressurised mist and may help patients who aren’t candidates for more extensive surgery.
@thecancersurvivorsclub.comA new cancer immunotherapy has entered its first human trial. DISP-10 aims to tag solid tumour cells so engineered CAR T cells can find and attack them, initially in advanced gastrointestinal cancers.
@thecancersurvivorsclub.comEncouraging lung cancer results: Imdelltra plus Imfinzi significantly improved overall survival in a late-stage trial for extensive-stage small-cell lung cancer.
@thecancersurvivorsclub.comA first for breast cancer treatment. The FDA has approved camizestrant for certain advanced breast cancers, guided by a blood test that can detect treatment resistance before it appears on scans.